Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph not_applicable
3
60%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (40.0%)
N/A3 (60.0%)

Trials by Status

recruiting360%
not_yet_recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

NCT07672431
recruitingnot_applicable

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

NCT07118202
not_yet_recruitingnot_applicable

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

NCT07227831
recruitingphase_2

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

NCT07130903
recruitingphase_2

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

NCT06576115

Clinical Trials (5)

Showing 5 of 5 trials
NCT07672431Not Applicable

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

Not Yet Recruiting
NCT07118202Not Applicable

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

Recruiting
NCT07227831Not Applicable

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Not Yet Recruiting
NCT07130903Phase 2

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Recruiting
NCT06576115Phase 2

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5